Advertisement

Erste Ergebnisse der Pentamidinaerosoltherapie der HIV-assoziierten leichten und mittelschweren Pneumocystis carinii Pneumonie (PcP) (im Rahmen einer multizentrischen Studie)

  • A. Meyer
  • M. Dietrich
Conference paper

Zusammenfassung

Die PcP ist die häufigste HIV-assoziierte, lebensbedrohliche opportunistische Infektion. Sie tritt verschiedenen Berichten zufolge, bei 35–80% der Patienten mit Aids auf (Mills 1986; Glatt et al. 1988; Murray et al. 1984). Unsere Erfahrungen am Tropeninstitut Hamburg bei der bisherigen Betreuung von 202 Patienten im Stadium Aids entsprechen dieser Angabe: Von unseren Patienten entwickelten 96 (47%) im Rahmen der HIV-Infektion eine oder mehrere Episoden einer PcP. Für 65 (32%) Patienten manifestierte die erste PcP den Übergang des Krankheitsverlaufes definitionsgemäß in das Stadium Aids (Stand 1988).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allegra CJ et al. (1987) Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Eng J Med 317: 978–985CrossRefGoogle Scholar
  2. Conte JE, Hollander H, Golden JA (1987) Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. Ann Intern Med 107: 495–498PubMedGoogle Scholar
  3. Debs R (1987) Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother 31: 37–41PubMedGoogle Scholar
  4. Gilman TM et al. (1986) Eflornithine treatment of Pneumocystis carinii pneumonia in Aids. Jama 256: 2197–2198PubMedCrossRefGoogle Scholar
  5. Girard PJ et al. (1988) Ultrasonic nebulised pentamidine for Pneumocystis pneumonia. Lancet I: 1165PubMedCrossRefGoogle Scholar
  6. Girard PM et al. (1987) Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 31: 978–981PubMedGoogle Scholar
  7. Glatt A, Chirgwin K, Landesman SH (1988) Treatment of infections associated with human immunodeficiency virus. N Engl J Med 318:1439–1448PubMedCrossRefGoogle Scholar
  8. Goa KL, Campoli-Richards DM (1987) Pentamidine isethionate. Drugs 33: 242–258PubMedCrossRefGoogle Scholar
  9. Godfrey-Faussett P, Miller RF, Semple SJG (1988) Nebulised pentamidine. Lancet I: 645–648PubMedCrossRefGoogle Scholar
  10. Kovacs JA, Masur H (1988) Pneumocystis carinii pneumonia: Therapy and prophylaxis. J Infect Dis 158: 254–259PubMedCrossRefGoogle Scholar
  11. Leoung GS et al. (1986) Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 105: 45–48PubMedGoogle Scholar
  12. Marcus J et al. (1986) Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 105: 37–44Google Scholar
  13. Mills J (1986) Pneumocystis carinii and toxoplasma gondii infections in patients with Aids. Rev Infect Dis 8:1011CrossRefGoogle Scholar
  14. Montgomery AB et al. (1987) Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet II: 480–482PubMedCrossRefGoogle Scholar
  15. Murray JF et al. (1984) Pulmonary complications of Aids. N Engl J Med 310:1682–1688PubMedCrossRefGoogle Scholar
  16. Sattler F (1988) Trimetrexate and leucovorin for Pneumocystis carinii pneumonia. (4th International Conference on Aids, Stockholm, June 12–16, abstr)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • A. Meyer
  • M. Dietrich

There are no affiliations available

Personalised recommendations